Boceprevir for previously treated chronic HCV genotype 1 infection.
暂无分享,去创建一个
Stefan Zeuzem | P. Marcellin | J. Albrecht | B. Bacon | Z. Goodman | S. Zeuzem | M. Burroughs | R. Esteban | S. Gordon | E. Lawitz | F. Poordad | H. Sings | Zachary D Goodman | Eric Lawitz | John M Vierling | Patrick Marcellin | Rafael Esteban | Bruce R Bacon | Fred Poordad | Stuart C Gordon | Heather L Sings | J. Vierling | Navdeep Boparai | Janice K Albrecht | Margaret Burroughs | Clifford A Brass | C. Brass | N. Boparai
[1] William M. Lee,et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. , 2009, The New England journal of medicine.
[2] Stefan Zeuzem. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? , 2004 .
[3] F. Negro. Adverse effects of drugs in the treatment of viral hepatitis. , 2010, Best practice & research. Clinical gastroenterology.
[4] P. Marcellin,et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.
[5] P. Kwo,et al. Peginterferon alfa‐2b and weight‐based or flat‐dose ribavirin in chronic hepatitis C patients: A randomized trial , 2007, Hepatology.
[6] P. Killenberg,et al. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. , 2004, The New England journal of medicine.
[7] S. Zeuzem. Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well? , 2004, Annals of Internal Medicine.
[8] J. Reichen,et al. Peginterferon alfa-2a in patients with chronic hepatitis C. , 2000, The New England journal of medicine.
[9] oseph,et al. PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS , 2000 .
[10] J. Hoofnagle,et al. Mechanism of action of interferon and ribavirin in treatment of hepatitis C , 2005, Nature.
[11] P. Kwo,et al. Boceprevir, an NS3 protease inhibitor of HCV. , 2009, Clinics in liver disease.
[12] M. Manns,et al. Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. , 2009, Current opinion in investigational drugs.
[13] Sprint Investigators,et al. Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .
[14] E. Herrmann,et al. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms , 2008, Liver international : official journal of the International Association for the Study of the Liver.
[15] J. Hoofnagle,et al. Peginterferon and ribavirin for chronic hepatitis C. , 2006, The New England journal of medicine.
[16] Thomas F. Smith,et al. Evaluation of the TRUGENE HCV 5′NC Genotyping Kit with the New GeneLibrarian Module 3.1.2 for Genotyping of Hepatitis C Virus from Clinical Specimens , 2003, Journal of Clinical Microbiology.
[17] M. Shiffman,et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. , 2000, The New England journal of medicine.
[18] D. Harnois. Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection , 2009 .
[19] M. Manns,et al. Telaprevir for previously treated chronic HCV infection. , 2010, The New England journal of medicine.
[20] M. Manns,et al. Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.